Protalix Biotherapeutics Inc (PLX) - Net Assets
Based on the latest financial reports, Protalix Biotherapeutics Inc (PLX) has net assets worth $48.23 Million USD as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($82.35 Million) and total liabilities ($34.12 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Protalix Biotherapeutics Inc asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $48.23 Million |
| % of Total Assets | 58.57% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 648.61 |
Protalix Biotherapeutics Inc - Net Assets Trend (1996–2025)
This chart illustrates how Protalix Biotherapeutics Inc's net assets have evolved over time, based on quarterly financial data. Also explore PLX total assets for the complete picture of this company's asset base.
Annual Net Assets for Protalix Biotherapeutics Inc (1996–2025)
The table below shows the annual net assets of Protalix Biotherapeutics Inc from 1996 to 2025. For live valuation and market cap data, see Protalix Biotherapeutics Inc stock valuation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $48.23 Million | +11.62% |
| 2024-12-31 | $43.21 Million | +28.72% |
| 2023-12-31 | $33.57 Million | +415.50% |
| 2022-12-31 | $-10.64 Million | -76.28% |
| 2021-12-31 | $-6.04 Million | +77.68% |
| 2020-12-31 | $-27.04 Million | +61.55% |
| 2019-12-31 | $-70.32 Million | -32.98% |
| 2018-12-31 | $-52.88 Million | -68.99% |
| 2017-12-31 | $-31.29 Million | -214.28% |
| 2016-12-31 | $-9.96 Million | -191.58% |
| 2015-12-31 | $10.87 Million | +119.56% |
| 2014-12-31 | $-55.60 Million | -106.34% |
| 2013-12-31 | $-26.95 Million | -702.68% |
| 2012-12-31 | $-3.36 Million | +87.13% |
| 2011-12-31 | $-26.08 Million | -130.30% |
| 2010-12-31 | $-11.32 Million | -171.29% |
| 2009-12-31 | $15.88 Million | -64.18% |
| 2008-12-31 | $44.35 Million | -30.37% |
| 2007-12-31 | $63.69 Million | +162.25% |
| 2006-12-31 | $24.28 Million | +2555.64% |
| 2005-12-31 | $914.43K | +84.60% |
| 2004-12-31 | $495.36K | -24.42% |
| 2003-12-31 | $655.43K | -17.67% |
| 2002-12-31 | $796.15K | -15.83% |
| 2001-12-31 | $945.91K | -29.61% |
| 2000-12-31 | $1.34 Million | -15.42% |
| 1999-12-31 | $1.59 Million | -52.64% |
| 1998-12-31 | $3.35 Million | -- |
| 1997-12-31 | $0.00 | -- |
| 1996-12-31 | $0.00 | -- |
Equity Component Analysis
This analysis shows how different components contribute to Protalix Biotherapeutics Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 38499700000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $80.00K | 0.17% |
| Other Components | $433.15 Million | 898.09% |
| Total Equity | $48.23 Million | 100.00% |
Protalix Biotherapeutics Inc Competitors by Market Cap
The table below lists competitors of Protalix Biotherapeutics Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Ekovest Bhd
KLSE:8877
|
$156.35 Million |
|
Soechi Lines Tbk
JK:SOCI
|
$156.35 Million |
|
Azerion Group N.V.
AS:AZRN
|
$156.41 Million |
|
OrganiGram Holdings Inc
TO:OGI
|
$156.42 Million |
|
Smith-Midland Corp
NASDAQ:SMID
|
$156.28 Million |
|
Arbor Technology
TWO:3594
|
$156.26 Million |
|
Bitcoin Group SE
XETRA:ADE
|
$156.20 Million |
|
Anteris Technologies Global Corp. Common Stock
NASDAQ:AVR
|
$156.14 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Protalix Biotherapeutics Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 43,211,000 to 48,230,000, a change of 5,019,000 (11.6%).
- Net loss of 6,604,000 reduced equity.
- Share repurchases of 9,326,000 reduced equity.
- New share issuances of 6,812,000 increased equity.
- Other factors increased equity by 14,137,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-6.60 Million | -13.69% |
| Share Repurchases | $9.33 Million | -19.34% |
| Share Issuances | $6.81 Million | +14.12% |
| Other Changes | $14.14 Million | +29.31% |
| Total Change | $- | 11.62% |
Book Value vs Market Value Analysis
This analysis compares Protalix Biotherapeutics Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.42x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1996-12-31 | $0.00 | $2.10 | x |
| 1997-12-31 | $0.00 | $2.10 | x |
| 1998-12-31 | $73.51 | $2.10 | x |
| 1999-12-31 | $30.45 | $2.10 | x |
| 2000-12-31 | $33.47 | $2.10 | x |
| 2001-12-31 | $29.30 | $2.10 | x |
| 2002-12-31 | $27.31 | $2.10 | x |
| 2003-12-31 | $22.48 | $2.10 | x |
| 2004-12-31 | $16.99 | $2.10 | x |
| 2005-12-31 | $28.91 | $2.10 | x |
| 2006-12-31 | $82.88 | $2.10 | x |
| 2007-12-31 | $9.48 | $2.10 | x |
| 2008-12-31 | $5.84 | $2.10 | x |
| 2009-12-31 | $2.06 | $2.10 | x |
| 2010-12-31 | $-1.40 | $2.10 | x |
| 2011-12-31 | $-3.08 | $2.10 | x |
| 2012-12-31 | $-0.37 | $2.10 | x |
| 2013-12-31 | $-2.92 | $2.10 | x |
| 2014-12-31 | $-5.99 | $2.10 | x |
| 2015-12-31 | $1.15 | $2.10 | x |
| 2016-12-31 | $-0.98 | $2.10 | x |
| 2017-12-31 | $-2.39 | $2.10 | x |
| 2018-12-31 | $-3.59 | $2.10 | x |
| 2019-12-31 | $-4.74 | $2.10 | x |
| 2020-12-31 | $-0.93 | $2.10 | x |
| 2021-12-31 | $-0.14 | $2.10 | x |
| 2022-12-31 | $-0.22 | $2.10 | x |
| 2023-12-31 | $0.41 | $2.10 | x |
| 2024-12-31 | $0.53 | $2.10 | x |
| 2025-12-31 | $0.61 | $2.10 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Protalix Biotherapeutics Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -13.69%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -12.52%
- • Asset Turnover: 0.64x
- • Equity Multiplier: 1.71x
- Recent ROE (-13.69%) is above the historical average (-20.39%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1996 | 0.00% | 0.00% | 0.00x | 0.00x | $131.68K |
| 1997 | 0.00% | 0.00% | 0.00x | 0.00x | $118.44K |
| 1998 | -34.19% | -14.27% | 1.68x | 1.42x | $-1.48 Million |
| 1999 | -62.82% | -28.07% | 1.74x | 1.29x | $-1.16 Million |
| 2000 | -7.89% | -10600000.00% | 0.00x | 1.42x | $-240.38K |
| 2001 | -34.78% | 0.00% | 0.00x | 1.08x | $-423.59K |
| 2002 | -18.84% | 0.00% | 0.00x | 1.10x | $-229.61K |
| 2003 | -21.47% | 0.00% | 0.00x | 1.12x | $-206.26K |
| 2004 | -32.31% | -37.23% | 0.76x | 1.14x | $-209.61K |
| 2005 | -628.37% | -3830.67% | 0.15x | 1.08x | $-5.84 Million |
| 2006 | -38.82% | -6284.67% | 0.01x | 1.11x | $-11.86 Million |
| 2007 | -35.30% | 0.00% | 0.00x | 1.07x | $-28.85 Million |
| 2008 | -50.54% | 0.00% | 0.00x | 1.15x | $-26.85 Million |
| 2009 | -197.95% | -8103.09% | 0.00x | 6.21x | $-33.03 Million |
| 2010 | 0.00% | -257.90% | 0.17x | 0.00x | $-27.87 Million |
| 2011 | 0.00% | -435.60% | 0.16x | 0.00x | $-33.92 Million |
| 2012 | 0.00% | -33.75% | 0.44x | 0.00x | $-11.28 Million |
| 2013 | 0.00% | -241.38% | 0.10x | 0.00x | $-25.10 Million |
| 2014 | 0.00% | -197.51% | 0.19x | 0.00x | $-24.38 Million |
| 2015 | 533.77% | 1329.90% | 0.04x | 8.94x | $56.95 Million |
| 2016 | 0.00% | -319.22% | 0.11x | 0.00x | $-28.37 Million |
| 2017 | 0.00% | -395.86% | 0.29x | 0.00x | $-80.31 Million |
| 2018 | 0.00% | -77.27% | 0.56x | 0.00x | $-21.17 Million |
| 2019 | 0.00% | -33.42% | 1.20x | 0.00x | $-11.24 Million |
| 2020 | 0.00% | -10.37% | 0.93x | 0.00x | $-3.82 Million |
| 2021 | 0.00% | -71.92% | 0.52x | 0.00x | $-26.98 Million |
| 2022 | 0.00% | -31.33% | 0.85x | 0.00x | $-13.86 Million |
| 2023 | 24.76% | 12.69% | 0.78x | 2.52x | $4.96 Million |
| 2024 | 6.79% | 5.49% | 0.73x | 1.70x | $-1.39 Million |
| 2025 | -13.69% | -12.52% | 0.64x | 1.71x | $-11.43 Million |
Industry Comparison
This section compares Protalix Biotherapeutics Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $173,871,658
- Average return on equity (ROE) among peers: -26.52%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Protalix Biotherapeutics Inc (PLX) | $48.23 Million | 0.00% | 0.71x | $156.31 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $98.85 Million |
| Abcellera Biologics Inc (ABCL) | $1.23 Billion | 12.85% | 0.25x | $1.59 Billion |
| Abeona Therapeutics Inc (ABEO) | $134.04 Million | -42.28% | 0.30x | $309.44 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $-18.59 Million | 0.00% | 0.00x | $181.29 Million |
| Abpro Holdings, Inc. (ABP) | $-75.73 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $189.45 Million | -60.80% | 0.14x | $795.12 Million |
| Arbutus Biopharma Corp (ABUS) | $200.23 Million | -28.52% | 0.14x | $854.72 Million |
| ABVC Biopharma Inc (ABVC) | $-5.75 Million | 0.00% | 0.00x | $27.18 Million |
| Abivax SA American Depositary Shares (ABVX) | $56.72 Million | -25.23% | 0.07x | $9.67 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $52.99 Million | -121.23% | 0.22x | $3.61 Billion |
About Protalix Biotherapeutics Inc
Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company provides Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also d… Read more